Upregulation of IGF-IIRα intensifies doxorubicin-induced cardiac damage

Area of Science:

• Cardiology
• Molecular Biology
• Pharmacology

Background:

• Doxorubicin is a potent anticancer drug, but its use is limited by cardiotoxicity.
• The precise mechanisms underlying doxorubicin-induced cardiotoxicity are not fully understood.
• Insulin-like growth factor receptor type II alpha (IGF-IIRα) is a newly identified stress-inducible protein.

Purpose of the Study:

• To investigate the role of IGF-IIRα in doxorubicin-induced cardiac stress.
• To determine how IGF-IIRα overexpression affects cardiac structure and function under doxorubicin treatment.

Main Methods:

• In vitro studies using H9c2 cells.
• In vivo studies using transgenic rats overexpressing IGF-IIRα in the heart (SD-TG [IGF-IIRα]).
• Analysis of cardiac structural and functional markers, protein expression (e.g., p-Akt, ERβ/α, ANP, cTn-I, p53, Bax, Cyt C, AT1R, ERK1/2, p38), and reactive oxygen species (ROS) production.

Main Results:

• IGF-IIRα overexpression led to cardiac abnormalities and functional impairments, which were worsened by doxorubicin.
• Elevated levels of cardiac hypertrophy and apoptosis factors were observed with IGF-IIRα overexpression.
• Reduced survival proteins (p-Akt, ERβ/α) and increased cardiac damage markers (ANP, cTn-I, p53, Bax, Cyt C) were noted.
• IGF-IIRα increased ROS production, further aggravated by doxorubicin.

Conclusions:

• IGF-IIRα is a novel stress-induced protein that disrupts cardiac homeostasis.
• IGF-IIRα cumulatively exacerbates doxorubicin-induced cardiac injury, leading to impaired heart function and cardiomyopathy.